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Abstract
Background: Inclusion of new biomarkers to improve a personalized treatment approach for oropharyngeal
squamous cell carcinoma (OPSCC) is urgently needed. Hypomethylation of the Long interspersed nucleotide
element-1 (LINE-1) repetitive elements, a widely accepted surrogate of overall genomic DNA methylation content,
was found to be associated with a poor prognosis in several cancers. At present, no studies have investigated the
influence of LINE-1 methylation levels on OPSCC relapse. The main goal of this study was the evaluation of the
prognostic value of LINE-1 methylation status in predicting early tumor relapse in locally advanced OPSCC.
Methods: We retrospectively reviewed a cohort of 77 patients with stage III–IVB OPSCC. Methylation of LINE-1
repetitive sequences was evaluated by real-time quantitative methylation-specific PCR in formalin-fixed
paraffin-embedded tissues. The prognostic relevance of LINE-1 methylation was assessed by comparing
patients who relapsed within 2 years from the end of treatment (cases) with those who did not (controls).
Results were validated in an independent cohort of 33 patients with OPSCC.
Results: With respect to early OPSCC relapse, the mean LINE-1 methylation level was significantly lower in
relapsed cases than in control group (p < 0.01). Interestingly, LINE-1 methylation was lower in relapsed cases
than in controls in both HPV16-negative and HPV16-positive OPSCC patients, even if statistical significance was
reached only for the former group (p = 0.01). LINE-1 methylation levels were also significantly reduced in relapsed cases
with respect to the controls in OPSCC current smokers (p = 0.02). Consistently, in HPV16-negative current smokers,
OPSCC relapse was significantly associated with decreased levels of LINE-1 methylation (p = 0.02). Using logistic
regression model, we found that patients with hypomethylated LINE-1 were associated with a 3.5 higher risk of
early relapse than hypermethylated ones (OR = 3.51; 95% CI 1.03–12.00). Adjustment for potential confounders
did not substantially change the risk magnitude. Results from the validation cohort confirmed the lower LINE-1
methylation in patients who early relapsed compared to relapse-free patients.
Conclusions: LINE-1 hypomethylation is associated with higher risk of early relapse in stage III–IVB OPSCC.
Further validation in a prospective study is needed for its application in daily clinical practice.
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Background
Head and neck cancers rank as the sixth most frequent
cancer worldwide with the most common type being the
head and neck squamous cell carcinoma (HNSCC). Up
to 30% of HNSCC is represented by oropharyngeal squa-
mous cell carcinoma (OPSCC), which originates in the
tonsils, base of the tongue, soft palate, and posterior
pharyngeal wall, and accounts for approximately 123,000
incident cases diagnosed worldwide each year [1]. To-
bacco use and heavy alcohol consumption represent the
main risk factors for HNSCC development, and they can
act synergistically to increase the risk of this malignancy
[2]. In the last years, the incidence of HNSCC has been
decreasing in developed countries due to a reduction in
tobacco exposure. Nevertheless, there is a concomitant
increase in the incidence of OPSCC as a result of trans-
forming infections by high-risk alpha human papilloma-
virus (HR α-HPV) types [3, 4]. HR α-HPVs are sexually
transmitted viruses which can affect the crypt epithelium
of the palatine and lingual tonsils, ultimately leading to a
malignant phenotype. HPV-driven OPSCC predominantly
affects young men and typically non-smokers. High-risk
HPV is present in 45–90% of OPSCC, but this figure
has been reported to dramatically vary according to
geographic area [3, 5].
OPSCC is frequently diagnosed when already symptom-
atic and, therefore, in advanced stages. The treatment of
OPSCC frequently requires a multimodality approach that
may include surgery, radiotherapy (RT), and chemother-
apy administered in different combinations [4]. Treatment
decision for OPSCC patients requires consideration of
tumor subsite and stage, functional outcomes and mor-
bidity associated with various treatment approaches,
and patient-specific factors such as performance status,
comorbidities, and preference. However, as different
combined treatments can affect the quality of life, the
need to identify biomarkers that could guide treatment
decisions and/or predict relapse of OPSCC patients is a
pressing issue. In particular, relapse develops in a consid-
erable number of locally advanced OPSCC patients, and
the risk of locoregional relapse after radical treatment var-
ies between 20 and 52% [6]. Despite recent improvements
in both surgical and radiotherapy treatments, OPSCC re-
lapse is for the most part a time-limited phenomenon,
since the majority of recurrences appears within the first
2 years after treatment for both HPV-positive (66.0%) and
HPV-negative (89.3%) OPSCC patients [7]. Additionally,
OPSCC patients who relapse within 1 year of initial
treatment have a significantly worse prognosis and are
generally thought to have radiation-resistant tumors
[8]. Interestingly, OPCSS relapse usually occurs earlier
in HPV-negative than in HPV-positive patients (median
time to recurrence 9.9 vs. 19.6 months) [7]. Along this
line, it has been reported that patients with HPV-positive
OPSCC have more favorable outcomes than those with
HPV-negative OPSCC [9–12] probably due to a stimula-
tion of the immune response directed to HPV-specific an-
tigens that may play a role in the improved response to
therapy [13–15]. Although HPV positivity represents a
strong prognostic factor for both improved survival and
reduced risk of relapse, there is a subset of HPV-positive
OPSCC patients who still experience poor outcomes [16].
Furthermore, HPV-negative OPSCC patients, who have
an even higher risk of relapse despite intensive therapy,
are still lacking suitable prognostic biomarkers for clinical
outcome prediction. From the above considerations, it
emerges that the identification of new prognostic molecu-
lar markers is urgently needed to more precisely identify
OPSCC patients at higher risk of early relapse.
The biological diversity that characterizes tumor sub-
sets with different prognosis is an important background
for the identification of molecular markers of potential
clinical utility. In this regard, several studies focused on
mechanisms underlying the differences in clinical and
molecular behavior between HPV-positive and HPV-
negative OPSCC [16–18]. Recent data suggest that epigen-
etic changes deeply influence the biology of OPSCC and
may contribute, at least in part, to the different therapeutic
responses shown by HPV-positive and HPV-negative
OPSCC [19]. In this context, methylation of genomic DNA
at CpG dinucleotides undoubtedly represents one of
the most extensively characterized epigenetic regulators
of gene expression [20]. Aberrant DNA hypermethylation
represents an early and frequent molecular event during
multistep carcinogenesis in OPSCC, especially in long-
term tobacco users, along with prolonged alcohol con-
sumption [21–23]. However, a high frequency of promoter
DNA hypermethylation has also been observed in smoke-
less tobacco-associated OPSCC tissue and in correspond-
ing adjacent normal mucosa [24]. Besides gene-specific
hypermethylation, genome-wide hypomethylation might
contribute to tumorigenesis and cancer progression by
promoting genomic instability, reactivating endogenous
parasitic sequences, and inducing the expression of onco-
genes [25]. Extensive DNA hypomethylation in tumors oc-
curs frequently at repetitive sequences, including short
and long interspersed nuclear elements, segmental dupli-
cations, and sub-telomeric regions [26]. These findings
further validate the role of DNA methylation in maintain-
ing the stability of the human genome and the suppression
of transposable elements in mammalian cells.
The increasing role of aberrant methylation in OPSCC
biology strongly suggests for the opportunity to test
methylation markers as potential indicators of disease
prognosis. In addition to studies investigating the prog-
nostic role of the methylation status of specific genes,
the study of the methylome, which encompasses the to-
tality of the genomic DNA methylated sites, is gaining
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ever growing interest due to its promising value as prog-
nostic marker in human cancer [27, 28]. Along this line,
hypomethylation of the long interspersed nucleotide
element-1 (LINE-1) repetitive elements, a widely accepted
surrogate of overall genomic DNA methylation content,
has been associated with a poorer overall and/or
progression-free survival in many different tumor types
[29–34]. However, LINE-1 hypomethylation also corre-
lated with improved overall survival in several malig-
nancies, thus suggesting that the underlying biological
effects of LINE-1 hypomethylation on patient outcome
may depend on tumor histotype [35, 36]. In addition to
its potential role as a prognostic biomarker, LINE-1
methylation level may be useful for assessing the risk of
cancer relapse and/or predicting the therapeutic efficacy of
cancer treatment regimens [37]. Although several studies
have evaluated the prognostic role of LINE-1 methylation
in HNSCC, their results are still inconclusive [38–41].
Furthermore, no prior study has specifically investigated
the influence of the overall level of genomic DNA methy-
lation on early OPSCC relapse risk. On these grounds, we
designed a retrospective case-control study aimed at
evaluating whether LINE-1 methylation could represent a
useful prognostic molecular marker in predicting early
tumor relapse in locally advanced OPSCC, in order to im-
prove the clinical management of the disease.
Methods
Patients
We retrospectively reviewed the records of 104 patients
who fulfilled the following inclusion criteria: (i) stage
III–IVB OPSCC; (ii) managed with curative intent with
radiotherapy ± chemotherapy or radiotherapy + surgery ±
chemotherapy, in accordance with current clinical practice;
(iii) treated between 2001 and 2013 at the National Cancer
Institute of Aviano (Italy). Clinical data, socio-demographic
characteristics, smoking habits, and treatment were re-
trieved from medical records. However, 27 patients were
excluded because of inadequate tumor tissue sample or in-
complete clinical data, thus leaving 77 patients eligible for
the final analysis. The treatment planning with respect to
surgical vs. nonsurgical approaches was discussed by a
multidisciplinary tumor board for optimal decision-making.
Treatment policies were based on offering definitive
chemo-radiotherapy to patients with stage III–IVB OPSCC
who were not suitable for conservative surgery. Patients
were followed at regular intervals to determine tumor sta-
tus until death or 31 December 2015, whichever came first.
Early relapse was defined as that diagnosed in the first
2 years after curative intent. Twenty-eight patients who re-
lapsed within 24 months from the end of the treatment
(cases) were compared to those who were relapse-free for
at least 24 months after the treatment (controls, n = 49). A
separate validation cohort of 33 patients who underwent
treatment from 2003 to 2014 was then recruited from the
Treviso Regional Hospital. Treatment planning, treatment
delivery, and follow-up strategies were applied in the same
manner as in the discovery cohort. All tumors were reclas-
sified according to the American Joint Committee on
Cancer 7th Edition [42].
In both discovery and validation cohorts, a representa-
tive neoplastic sample was collected for each patient at the
time of surgical resection or biopsy from a non-necrotic
area of the carcinoma. Samples from OPSCC patients
were taken before starting any treatments. Hematoxylin-
and eosin-stained slides of the tumors were reviewed by
the pathologist, who marked the areas of the tumor and
adjacent non-neoplastic tissue. The study was limited to
neoplastic lesion that contained ≥70% neoplastic cells. The
study was approved by the local Independent Ethic Com-
mittees. Participants provided written informed consent
for inclusion in the study.
Quantitation of HPV16 E6 DNA using real-time quantitative
PCR analysis
Genomic DNA was extracted from OPSCC formalin-fixed
paraffin-embedded (FFPE) tissues using the QIAamp DNA
FFPE Tissue Kit (Qiagen), following the manufacturer’s
protocol. DNA concentration was measured with the Qubit
Fluorometer using the Qubit dsDNA High Sensitivity Assay
Kit (Life Technologies). The quantification of HPV16 DNA
was performed with the ABI prism 7700 Sequence Detec-
tion System (Life Technologies) by using specific primers
for the amplification of a region spanning the E6 gene of
the HPV16 genome [40]. SYBR green quantitative HPV16-
PCR reactions were performed in triplicate on 10 ng of
DNA in a final volume of 25 μl 1 X SYBR Green Master
Mix (Life Technologies) at 95 °C for 10 min, followed by
45 cycles at 95 °C for 15 s and at 60 °C for 1 min, and dis-
sociation performed at 95 °C for 15 s, 60 °C for 20 s, and
95 °C for 15 s. SYBR Green primer sets were as follows:
HPV16 E6, forward CTGCAATGTTTCAGGACCCA and
reverse TCATGTATAGTTGTTTGCAGCTCTG. Known
amounts of E6 DNA molecules were used to generate an
absolute standard curve. The copy number of E6 DNA was
determined in each sample by extrapolation of the standard
curve. E6 copy number ≥100 copy/well was regarded as
positive.
Quantitative methylation-specific PCR analysis for the
methylation levels of LINE-1
Genomic DNA was obtained from OPSCC FFPE tissues
in quantities sufficient for bisulfite treatment. Bisulfite
conversion was carried out on 500 ng genomic DNA
using EZ DNA Methylation-Gold™ Kit (Zymo Research),
according to the manufacturer’s protocol. SYBR Green
quantitative methylation-specific PCR (qMSP) was per-
formed with the ABI prism 7700 Sequence Detection
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System (Life Technologies). QMSP reactions were carried
out in triplicate on 2 μl of bisulfite-modified genomic DNA
in a final volume of 25 μl 1 X SYBR Green Master Mix
(Life Technologies), as described above. LINE-1 qMSP re-
actions were run in parallel with SYBR Green primers for
methylated (forward, 5′-CGCGAGTCGAAGTAGGGC-3′;
reverse, 5′-ACCCGATTTTCCAAATACGACCG-3′) and
for unmethylated sequence (forward, 5′-TGTGTGTGAGT
TGAAGTAGGGT-3′; reverse, 5′-ACCCAATTTTCCAAA
TACAACCATCA-3′) [43]. Known amounts of LINE-1
methylated and unmethylated DNA molecules were used
to generate absolute standard curves. The copy number of
methylated or unmethylated sequences for each target gene
was established by extrapolation from the standard curves.
The percentage of methylation was defined as the ratio be-
tween methylated molecules and the sum of methylated
and unmethylated molecules.
Statistical analysis
Despite recurrence is a time-dependent outcome, in head
and neck cancer patients, early recurrence (i.e., within
2 years from end of treatment) is a major predictor of
poor prognosis, with little impact of the time this event
occurs [7, 8]. Therefore, in the present case-control study,
we focused on the early recurrence itself rather than on
the time to relapse, considering it as a binary variable. As
a consequence, patients were followed up for a maximum
of 2 years after the end of treatment.
Cases and controls were compared in terms of socio-
demographic characteristics (age and gender), lifestyle
(smoking status), clinical (tumor size, number of lymph
nodes involved, and clinical stage), and pathologic factors
(HPV16 status). All variables were categorized, and cases
and controls were compared using Fishers’ exact test.
LINE-1 methylation levels between cases and controls and
across strata were compared using the non-parametric
Kruskal–Wallis test. The prognostic relevance of LINE-1
methylation and other covariates on OPSCC relapse was
assessed by calculation of odds ratios (OR) and corre-
sponding 95% confidence intervals (CI) through univariate
and multivariate logistic regression model. The statistical
analyses were carried out using R Statistical Software
(Foundation for Statistical Computing, Vienna, Austria)
for Windows. All statistical tests were two-sided, and sig-
nificance was claimed for p ≤ 0.05.
The association between LINE-1 methylation and
cancer relapse was further investigated across cancer
risk categories. Using information on HPV16 status and
smoking habits (current smoking was considered as a
proxy of smoking >20 pack year), OPSCC were catego-
rized as low risk of early relapse (non-smokers HPV16-
positive), intermediate risk (smokers HPV16-positive or
non-smokers HPV16-negative), and high risk (smokers
HPV16-negative).
Results
Patients
The distributions of socio-demographic and clinico-
pathologic characteristics among cases and controls at
baseline are presented in Table 1. In the discovery set,
the median age of OPSCC patients was 59 (range 41–
87 years) and the majority of cases (67.9%) and controls
(67.4%) were men with a similar gender distribution be-
tween the two groups. Within the discovery cohort, 49 pa-
tients (64%) were classified as current smokers, while 14
(18%) were former smokers, and 14 (18%) have never
smoked. The HPV16 E6 DNA region was detected in 18
of 77 OPSCC patients (23.4%). Although HPV16 infection
appeared to have no effect on the likelihood of early tumor
relapse (p = 0.58), the percentage of OPSCC patients posi-
tive for HPV16 E6 DNA was higher in controls when
compared to cases. There was no statistically significant
difference between the two groups regarding treatment
approaches, and also, all the other socio-demographic and
clinico-pathologic features included in the analysis showed
no statistically significant differences (Table 1).
LINE-1 methylation in OPSCC patients
Methylation of LINE-1 repetitive elements was evaluated
by qMSP analysis in DNA obtained from 77 OPSCC tis-
sues. LINE-1 methylation levels were largely heteroge-
neous (range, 6–94%) and were not correlated with age,
gender, tumor stage, and treatment administered (Fig. 1).
However, LINE-1 methylation level was significantly
higher in HPV16-positive OPSCC patients than in
HPV16-negative ones (median, 67.5 and 53.9%, respect-
ively; p = 0.02). Therefore, the interaction between LINE-
1 methylation levels and HPV16 infection was further
investigated according to their HPV status (Fig. 2). Inter-
estingly, LINE-1 methylation was lower in cases than in
controls in both HPV16-negative and HPV16-positive,
even if statistical significance was reached only among the
former group (p = 0.01). Similarly, LINE-1 methylation
was lower in cases than controls in smokers (p = 0.02).
Conversely, no statistically significant difference in LINE-1
methylation was found between cases and controls among
non-smokers OPSCC patients (Fig. 2), even if median level
was lower in cases than in controls. Finally, stratification
through HPV16 and smoking status into OPSCC early re-
lapse risk groups revealed lower levels of LINE-1 methyla-
tion in OPSCC cases belonging to the intermediate- and
high-risk groups, even though the statistical significance
was observed only in the high-risk group (p = 0.02) (Fig. 2).
The impact of LINE-1 methylation on outcome
A logistic regression analysis was performed to investigate
the association of LINE-1 methylation levels and 2-year
OPSCC relapse. LINE-1 methylation level <50% was asso-
ciated to a higher risk of early disease relapse (OR = 3.51;
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95% CI 1.03–12.00) compared to ≥70%. All other variables
evaluated did not significantly associate with outcome,
though a trend towards an increased risk (p = 0.11) was
observed for tumor stage. Adjustment for potential con-
founders did not substantially modify the risk magnitude,
affecting only confidence intervals. LINE-1 hypomethy-
lation was further analyzed as a continuous variable,
reporting an increase in early relapse risk of 50% (95%
CI 1.13–2.01) for every decrease of 10% in methylation
(Table 1).
Validation study
Study results were validated on an independent cohort
of 33 OPSCC patients (Table 2). The validation set had
Table 1 Distribution of socio-demographic and clinical features, odds ratio (OR) of relapse, and corresponding 95% confidence
intervals (CI) in 28 OPSCC patients who recurred within 24 months from end of treatment (cases) and 49 OPSCC patients who
did not (controls)
Variables Cases, n = 28 Controls, n = 49 OR (95% CI)a OR (95% CI)b
n (%) n (%)
Gender
Male 19 (67.9) 33 (67.4) 1f 1f
Female 9 (32.1) 16 (32.7) 1.07 (0.38–2.97) 1.08 (0.37–3.18)
Age (years)
<55 10 (35.7) 18 (36.7) 1f 1f
55–59 10 (35.7) 12 (24.5) 1.52 (0.47–4.91) 1.66 (0.49–5.66)
≥60 8 (28.6) 19 (38.8) 0.76 (0.25–2.37) 0.90 (0.27–3.00)
Smoking habits
Never 4 (14.3) 10 (20.4) 1f 1f
Former 3 (10.7) 11 (22.5) 0.62 (0.11–3.62) 0.66 (0.11–4.12)
Current 21 (75.0) 28 (57.1) 1.73 (0.46–6.54) 1.44 (0.32–6.45)
Nc, d
0–1 5 (17.9) 15 (31.3) 1f 1f
2–3 23 (82.1) 33 (68.7) 2.02 (0.63–6.55) 1.12 (0.42–2.99)
Tc, d
1–2 11 (39.3) 31 (64.6) 1f 1f
3–4 17 (60.7) 17 (35.4) 3.23 (1.18–8.86) 1.92 (1.02–3.62)
Stage
III 4 (13.8) 12 (25.0) 1f 1f
IV 25 (86.2) 36 (75.0) 2.77 (0.68–11.30) 2.44 (0.58–10.29)
HPV16
Negative 23 (82.1) 36 (73.5) 1f 1e
Positive 5 (17.9) 13 (26.5) 0.59 (0.18–1.93) 0.92 (0.24–3.61)
Therapyc
RT ± CT 16 (57.1) 21 (42.9) 1f 1f
RT + CH ± CT 12 (42.9) 28 (57.1) 0.53 (0.20–1.45) 0.48 (0.16–1.51)
LINE-1 methylation
≥70% 6 (21.4) 19 (38.8) 1f 1f
50 to <70% 9 (32.1) 17 (34.7) 1.68 (0.48–5.83) 2.18 (0.53–8.97)
<50% 13 (46.4) 13 (26.5) 3.51 (1.03–12.00) 4.12 (1.01–16.91)
Continuous 10% decreasee 1.45 (1.13–1.87) 1.50 (1.13–2.00)
aEstimated through logistic regression model adjusted for sex and age
bAs footnote a, plus adjustment for smoking habits, stage, and HPV16
cN number of lymph nodes involved, T tumor size, RT radiotherapy, CT chemotherapy, CH surgery
dThe sum does not add up to total because of missing values
eLINE-1 methylation analyzed as continuous variable, risk associated with 10% decrease in methylation
fReference category
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Fig. 1 LINE-1 methylation according to socio-demographic characteristics, smoking habits, tumor features, and surgical treatment. Black horizontal
bars represent the median values of LINE-1 methylation for each group. p values were determined by the non-parametric Kruskal–Wallis test
Fig. 2 LINE-1 methylation in patients who relapsed within 24 months from the end of treatment (cases) and in patients who did not (controls),
according to HPV16 status, current tobacco smoking, and risk group. Risk group was defined on HPV16 status and current tobacco smoking as
follow: low (HPV16+/non-smokers), intermediate (HPV16−/non-smokers or HPV16+/smokers), high (HPV16−/smokers). Black horizontal bars
represent the median values of LINE-1 methylation for each group. p values were determined by the non-parametric Kruskal–Wallis test
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similar distributions for most of the clinico-pathologic
characteristics examined with respect to the discovery
cohort. However, the validation cohort was older (p = 0.01),
which included a higher proportion of T3–4 cancers
(p < 0.01), and had a trend towards an increased preva-
lence of HPV16 infection (p = 0.11) than the discovery set.
The probability of 2-year OPSCC relapse estimated ac-
cording to the logistic model for case and controls is
shown in Fig. 3 for both the discovery and the validation
cohorts. In both cohorts, the risk of early relapse in-
creases with decreasing LINE-1 methylation level. The
estimated risks for each decrement of 1% were very
similar, being 1.04 (95% CI 1.01–1.06) in the discovery
set and 1.06 (95% CI 1.01–1.10) in the validation set.
Discussion
This is the first study showing that methylation of LINE-1
repetitive elements predicts the risk of early post-treatment
relapse in OPSCC patients. In fact, a progressively in-
creasing risk of 2-year OPSCC relapse was significantly
correlated with the decreasing of LINE-1 methylation.
By including confounder adjustments, such as HPV16
infection and smoking status, we found that low LINE-1
methylation level maintained its ability to identify OPSCC
patients at higher risk of early relapse. The positive valid-
ation of these results that we obtained on an independent
cohort of OPSCC patients confirms the strength of LINE-1
hypomethylation as a reliable tool for identifying a sub-
group of OPSCC patients with a high risk of early tumor
relapse. As such, these results potentially bear an important
clinical relevance both for improving treatment intensity
decisions as well as for defining most appropriate follow-up
procedures. Furthermore, the strength of the observed
prognostic correlation is supported by the consideration
that the study was carried out on a homogenous population
comprising stage III–VIB OPSCC patients who have under-
gone radiotherapy ± chemotherapy or radiotherapy + sur-
gery ± chemotherapy with curative intent.
Although there is growing evidence that global gen-
omic DNA methylation decreases with aging [44–46],
several studies did not observe an association between
LINE-1 hypomethylation and age [47, 48]. Consistent
with these data, we did not find any correlation between
LINE-1 hypomethylation and age in both discovery and
validation cohorts (Fig. 4). Similar to previous investigations
Table 2 Distribution of socio-demographic and clinical features
in 9 OPSCC patients who recurred within 24 months from end of
treatment (cases) and 24 OPSCC patients who did not (controls)
who served as validation set
Variable Cases, n = 9 Controls, n = 24 p valuec
n (%) n (%)
Gender
Male 4 (44.4) 17 (70.8) 0.23
Female 5 (55.6) 7 (29.2)
Age, years
<55 1 (11.1) 4 (16.7) 1.00
55–59 2 (22.2) 4 (16.7)
≥60 6 (66.7) 16 (66.7)
Smoking habits
Never 3 (33.3) 5 (20.8) 0.32
Former 1 (11.1) 1 (4.2)
Current 5 (55.6) 18 (75.0)
Na, b
0–1 3 (33.3) 9 (37.5) 1.00
2–3 6 (66.7) 15 (62.5)
Ta, b
1–2 3 (33.3) 8 (33.3) 1.00
3–4 6 (66.7) 16 (66.7)
Stage
III 2 (22.2) 6 (25.0) 1.00
IV 7 (77.8) 18 (75.0)
HPV16
Negative 8 (88.9) 12 (50.0) 0.06
Positive 1 (11.1) 12 (50.0)
Therapy
RT ± CT 3 (33.3) 12 (50.0) 0.46
RT + CH ± CT 6 (66.7) 12 (50.0)
aThe sum does not add up to total because of missing values
bN number of lymph nodes involved, T tumor size, RT radiotherapy,
CT chemotherapy, CH surgery
cFisher’s exact test
dStatistical comparison of the different characteristics in discovery and
validation series
Fig. 3 Predicted probability of relapse within 24 months from end
of treatment in the discovery set and in the validation set
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[39–41], in our study, LINE-1 methylation status was
different according to HPV16 infection. HPV-positive
and HPV-negative OPSCCs are driven by different
tumorigenic pathways [49], which are reflected in their
diverse clinical behavior [16]. Several studies highlighted
characteristic differences in gene expression profiles be-
tween HPV-negative and HPV-positive OPSCC, suggest-
ing that a better clinical outcome may be partially due to
HPV-related changes in the pattern of DNA methylation
[19]. HPV-positive tumors showed increased methylation
in the promoter region of tumor suppressor genes as com-
pared to HPV-negative tumors, in which global genomic
hypomethylation is more frequently observed [50]. Al-
though the exact mechanism of global genomic DNA
hypomethylation in HNSCC is still elusive, differences
in the expression and/or activity of DNA methyltransfer-
ases (DNMTs) may explain HPV-related differences among
OPSCC [41, 51]. In fact, evidence has been provided indi-
cating that the E6 and E7 HPV16 oncoproteins can directly
interact with DNMTs, thus stimulating their activity in vitro
[52]. Furthermore, it has been reported that the HPV gen-
ome itself may become hypermethylated following infection
or integration into host cells. This would represent a
defense mechanism against foreign agents that may alter
the expression patterns of HPV genes that are relevant for
infection and transformation [53]. Accordingly, in our
study, LINE-1 methylation status was different between
HPV16-positive and HPV16-negative OPSCC patients, be-
ing lower in the latter. In this setting, the lowest level of
LINE-1 element methylation was observed in HPV16-
negative OPSCC patients who relapsed within 2 years
(Fig. 2). Environmental factors, such as tobacco smoking,
have been associated with global DNA hypomethylation. In
fact, genotoxic exposure to cigarette smoke condensate and
heavy metals that are present in tobacco smoke may reduce
genomic DNA methylation [54]. Although the exact mech-
anism by which tobacco carcinogens affects global DNA
methylation is still unknown, the buccal mucosal cells of to-
bacco smokers were shown to have a reduced concentra-
tion of folate [55], which is required for the maintenance of
methylation patterns in DNA [56]. In addition, it has been
reported that chemical components present in tobacco
smoke can decrease folic acid and vitamin B12 levels [57],
thus suggesting they may alter the activity of the enzymatic
pathways required for DNA methylation. In our study,
OPSCC current smokers who relapsed within 2 years ex-
hibited reduced LINE-1 methylation levels when compared
to former and never smokers. Interestingly, the association
between smoking habits and LINE-1 hypomethylation was
stronger in HPV16-negative OPSCC cases, where tobacco
exposure and alcohol consumption represent the major
etiologic risk factor. Our observation suggests that distinct
molecular phenotypes may characterize relapse in HPV16-
negative OPSCC compared to those arising from HPV16
infection. Thus, within the poor prognosis of HPV16-
negative tumors, low LINE-1 methylation could identify a
subset of particularly high-risk patients that could benefit
from enhanced post-treatment surveillance. These findings
may highlight hypomethylation of LINE-1 as a promising
biomarker for prospective studies specifically focused on
HPV-negative OPSCC patients. In fact, the management of
patients with resectable, locally advanced high-risk OPSCC
is complex, and new predictive tools are awaited for select-
ing between surgical and nonsurgical approaches in this
setting.
In the last years, LINE-1 methylation level has been
widely considered as a surrogate marker for global DNA
methylation [36], and genomic DNA hypomethylation,
indicated by LINE-1 hypomethylation, has been fre-
quently associated with chromosomal instability which
represents a characteristic phenotype of more invasive
cancers having worse prognosis [58]. However, some
studies suggest LINE-1 hypomethylation may have itself
some biologic effects in promoting tumor progression.
This would occur through transcription of specific gen-
omic portions within the promoter of hypomethylated
LINE-1 elements that can lead to the aberrant expres-
sion of proto-oncogenes and/or non-coding RNA able to
enhance the tumor metastatic potential [59, 60]. Al-
though our findings may suggest a role for LINE-1 ele-
ments in tumor progression, further studies are required
to specifically investigate the potential mechanisms
by which genome-wide DNA hypomethylation may
affect the clinical course of OPSCC, especially in HPV-
negative patients.
Fig. 4 Relationships between LINE-1 methylation and age in the
discovery and validation sets. The linear regression is represented
by a scattered line (discovery set) and a bold line (validation set).
Regression line coefficients (b) are also reported for both lines
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Despite our results emphasize the prognostic role of
LINE-1 hypomethylation in early OPSCC relapse, our
study has some limitations. First of all, some factors that
may have a significant impact on genome-wide DNA
methylation (i.e., alcohol consumption, diet, and physical
activity) [61, 62] were not evaluated since the study
population was not prospectively recruited, and some
patient-related information could not be recorded at sur-
gery. Further, for smokers, we did not have information
on the amount of cigarettes smoked per day, so it was
not possible to calculate their “pack year.” Therefore,
current smoking was considered for evaluation of OPSCC
relapse risk profile. Second, the number of OPSCC patients
enrolled in this study was limited, precluding sufficient
power in subgroup analyses. Therefore, future prospective
studies are warranted to validate the prognostic potential of
LINE-1 methylation in a larger cohort of OPSCC patients.
Furthermore, the accurate methylation analysis of LINE-1
repetitive DNA elements in patients’ tissues before and
after OPSCC relapse would improve our understanding of
its mechanistic role in tumor biology and further support
its prognostic significance.
Conclusions
In summary, our results highlight the role of LINE-1 hy-
pomethylation in identifying OPSCC patients at higher
risk for early relapse, independently of other classic risk
factors. Accordingly, our findings suggest that the evalu-
ation of LINE-1 methylation status may greatly help in
guiding the post-treatment surveillance and/or the choice
of treatment intensity in OPSCC patients belonging to the
hypomethylated group. Future prospective studies with
larger sample populations need to be performed to con-
firm our findings.
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